The UCSF Helen Diller Family Comprehensive Cancer Center (HDFCCC) combines basic science, clinical research, epidemiology/cancer control and patient care from throughout the University of California, San Francisco system. UCSF’s long tradition of excellence in cancer research includes the Nobel Prize-winning work of J. Michael Bishop and Harold Varmus, who discovered cancer-causing oncogenes. Their work opened new doors for exploring genetic abnormalities that cause cancer and formed the basis for some of the most important cancer research happening today. In addition to the HDFCCC’s robust breast cancer research and treatment program, UCSF is home to the Center for BRCA Research, one of only two such centers in the US. Its mission is to provide a central resource for families with BRCA and other mutations to receive personalized care and planning for their long-term health and well-being. This is our opportunity to rethink how we treat and manage hereditary cancers.
For more information please visit www.cancer.ucsf.edu

At Endomag, we believe everyone deserves a better standard of cancer care. With many of the world’s best physicians and cancer hospitals using our technologies for breast cancer surgery, we’re helping to prevent avoidable operations and sparing women from potential complications. When surgery is necessary, we’ve improved outcomes for tens of thousands, through more precise and less invasive surgery. Most importantly, our techniques are giving patients greater access to the best standards of treatment worldwide.
With the Sentimag® probe, physicians can perform both advanced lesion localization with the Magseed® marker and sentinel node biopsies with the Magtrace® lymphatic tracer.
For more information please visit www.endomagnetics.com

Stryker is one of the world’s leading medical technology companies. We offer products and services that help improve patient and hospital outcomes. Stryker’s visualization platform enables surgeons to distinguish anatomy across minimally invasive and open procedures. Our history of innovation in advanced imaging is driven by the desire to allow you to see and do more. SPY Portable Handheld Imager (SPY-PHI) allows surgeons to visualize blood flow in vessels and related tissue perfusion during plastic, microsurgical, reconstructive and gastrointestinal procedures. SPY-PHI is a unique and versatile fluorescence imaging system that provides clinicians with a convenient solution for perfusion assessment.
For more information please visit www.stryker.com

Genomic Health, Inc. is the world’s leading provider of genomic-based diagnostic tests that help optimize cancer care, including addressing the overtreatment of the disease, one of the greatest issues in healthcare today. With its Oncotype IQ® Genomic Intelligence Platform, the company is applying its world-class scientific and commercial expertise and infrastructure to lead the translation of clinical and genomic data into actionable results for treatment planning throughout the cancer patient journey, from diagnosis to treatment selection and monitoring. The Oncotype IQ portfolio of genomic tests and services currently consists of the company’s flagship line of Oncotype DX® gene expression tests that have been used to guide treatment decisions for over 1 million cancer patients worldwide. The company is based in Redwood City, California, with international headquarters in Geneva, Switzerland.
For more information please visit www.genomichealth.com

PreludeDx was founded with the goal of providing better decision-making tools to breast cancer patients and physicians. Founded in 2009 with technology licensed from University of California San Francisco, PreludeDx has focused on developing breast cancer tools that will impact a patient’s treatment decision. Our mission is to provide tools that improve patient outcomes in breast cancer and reduce the overall cost burden to the healthcare system.
Patient Focused: We realize that every sample that comes through our laboratory has a patient behind it and it is our job to ensure that we handle each sample with care and provide results back to the patient and physician in a timely manner. PreludeDx exists to take care of the needs of our patients.
Quality First: We will put quality systems and processes first and foremost as we provide the highest quality results to our patients and physicians.
Driving Innovation: PreludeDx will strive to find new innovative tools and processes that assist patients and physicians for the better management of cancer.
DCISionRT is the only test capable of predicting an individual patient’s benefit from radiation therapy. Using DCISionRT provides you with 10-year Total and Invasive Recurrence Risk after breast conserving surgery as well as surgery with radiation therapy. No other test can do this.
For more information please visit www.preludedx.com